share_log

Transcode Therapeutics | DEF 14A: Definitive information statements

Transcode Therapeutics | DEF 14A: Definitive information statements

Transcode Therapeutics | DEF 14A：股东委托书决议
美股SEC公告 ·  10/28 16:05

Moomoo AI 已提取核心信息

TransCode Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually on November 22, 2024. The meeting will address three key proposals: the ratification of a securities issuance and sale agreement with ThinkEquity LLC, an amendment to the company's charter to effect a reverse stock split, and a proposal to adjourn the meeting if necessary to solicit additional votes. The reverse stock split aims to increase the market price of TransCode's common stock to comply with Nasdaq's minimum bid price requirement. The Board has recommended a range for the reverse stock split, from one-for-ten to one-for-forty, with the exact ratio to be determined by the Board. The ratification proposal seeks to address a compliance issue with Nasdaq Listing Rule 5635(d), which requires shareholder approval for certain transactions. The Board has fixed October 25, 2024, as the record date for stockholders entitled to vote. The company has also addressed potential delisting risks if compliance with Nasdaq's continued listing requirements is not regained.
TransCode Therapeutics, Inc. has announced a Special Meeting of Stockholders to be held virtually on November 22, 2024. The meeting will address three key proposals: the ratification of a securities issuance and sale agreement with ThinkEquity LLC, an amendment to the company's charter to effect a reverse stock split, and a proposal to adjourn the meeting if necessary to solicit additional votes. The reverse stock split aims to increase the market price of TransCode's common stock to comply with Nasdaq's minimum bid price requirement. The Board has recommended a range for the reverse stock split, from one-for-ten to one-for-forty, with the exact ratio to be determined by the Board. The ratification proposal seeks to address a compliance issue with Nasdaq Listing Rule 5635(d), which requires shareholder approval for certain transactions. The Board has fixed October 25, 2024, as the record date for stockholders entitled to vote. The company has also addressed potential delisting risks if compliance with Nasdaq's continued listing requirements is not regained.
TransCode Therapeutics, Inc.宣布将于2024年11月22日虚拟举行股东特别会议。 该会议将讨论三项关键提案：批准与ThinkEquity LLC的证券发行和销售协议，修订公司章程以实施股票的反向拆分，以及如有必要推迟会议以征求额外的投票。 反向股票拆分旨在提高TransCode普通股的市场价格，以符合纳斯达克的最低买盘价格要求。 董事会建议反向股票拆分的区间从一换十到一换四十，并由董事会确定确切的比例。 批准提案旨在解决与纳斯达克第5635(d)条上市规则的合规问题，该条对某些交易需股东批准。 董事会确定2024年10月25日为有权投票的股东记录日期。 该公司还解决了若未恢复与纳斯达克持续上市规定的合规性可能面临的潜在摘牌风险。
TransCode Therapeutics, Inc.宣布将于2024年11月22日虚拟举行股东特别会议。 该会议将讨论三项关键提案：批准与ThinkEquity LLC的证券发行和销售协议，修订公司章程以实施股票的反向拆分，以及如有必要推迟会议以征求额外的投票。 反向股票拆分旨在提高TransCode普通股的市场价格，以符合纳斯达克的最低买盘价格要求。 董事会建议反向股票拆分的区间从一换十到一换四十，并由董事会确定确切的比例。 批准提案旨在解决与纳斯达克第5635(d)条上市规则的合规问题，该条对某些交易需股东批准。 董事会确定2024年10月25日为有权投票的股东记录日期。 该公司还解决了若未恢复与纳斯达克持续上市规定的合规性可能面临的潜在摘牌风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间